New cancer drug combo tested for safety in advanced tumors
NCT ID NCT04457778
First seen May 08, 2026 · Last updated May 24, 2026 · Updated 1 time
Summary
This early-phase study tested a new drug called M6223, which targets the immune system to fight cancer. It was given alone or with another drug (bintrafusp alfa) to 58 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the best dose, not to cure the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Next Oncology
San Antonio, Texas, 78229, United States
-
Princess Margaret Cancer Centre
Toronto, Canada
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.